Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy consisting of three components: 1. **Intravenous Immunoglobulin (IVIG)**: A solution of human plasma proteins, particularly IgG antibodies with a broad spectrum of antibody activity. IVIG is prepared from large pools of human plasma collected from several thousand blood donors[7]. It strengthens the immune system's natural defenses by providing additional antibodies that help fight infections[1][2]. 2. **Methylprednisolone**: A synthetic glucocorticoid with anti-inflammatory properties. It's available in various formulations including oral tablets and injectable forms[8][9]. 3. **Anti-D Immunoglobulin**: Although not specifically detailed in the search results, anti-D is a specialized immunoglobulin that targets the Rhesus D antigen on red blood cells. This combination therapy is likely used for autoimmune conditions where multiple mechanisms of immune modulation are beneficial. IVIG provides antibody replacement and immunomodulation, methylprednisolone offers potent anti-inflammatory effects, and anti-D immunoglobulin provides targeted immune modulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-D + intravenous immunoglobulin + methylprednisolone.